Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adolescents and young adults (AYA) with acute myeloid leukemia (AML): real-world long-term results and age-specific outcomes.
Lalayanni C, Demosthenous C, Iskas M, Kelaidi C, Papathanasiou M, Syrigou A, Athanasiadou A, Papalexandri A, Batsis I, Vardi A, Polychronopoulou S, Sakellari I. Lalayanni C, et al. Among authors: papathanasiou m. Leuk Lymphoma. 2022 Dec;63(13):3128-3137. doi: 10.1080/10428194.2022.2113527. Epub 2022 Aug 24. Leuk Lymphoma. 2022. PMID: 36002396
Secondary Acute Myeloid Leukemia (sAML): Similarly Dismal Outcomes of AML After an Antecedent Hematologic Disorder and Therapy Related AML.
Lalayanni C, Gavriilaki E, Athanasiadou A, Iskas M, Papathanasiou M, Marvaki A, Mpesikli S, Papaioannou G, Mallouri D, Batsis I, Papalexandri A, Sakellari I, Anagnostopoulos A. Lalayanni C, et al. Among authors: papathanasiou m. Clin Lymphoma Myeloma Leuk. 2022 Apr;22(4):e233-e240. doi: 10.1016/j.clml.2021.09.019. Epub 2021 Oct 1. Clin Lymphoma Myeloma Leuk. 2022. PMID: 34756570
Long-term outcomes of total body irradiation plus cyclophosphamide versus busulfan plus cyclophosphamide as conditioning regimen for acute lymphoblastic leukemia: a comparative study.
Sakellari I, Gavriilaki E, Chatziioannou K, Papathanasiou M, Mallouri D, Batsis I, Bousiou Z, Bouziana S, Constantinou V, Douka V, Apostolou C, Iskas M, Lalayanni C, Athanasiadou A, Sotiropoulos D, Yannaki E, Gianouzakos V, Anagnostopoulos A. Sakellari I, et al. Among authors: papathanasiou m. Ann Hematol. 2018 Oct;97(10):1987-1994. doi: 10.1007/s00277-018-3383-9. Epub 2018 Jun 5. Ann Hematol. 2018. PMID: 29869673
Survival Advantage of Treosulfan Plus Fludarabine Before Allogeneic Hematopoietic Cell Transplantation for Older or Comorbid Patients With Myeloid Malignancies.
Sakellari I, Gavriilaki E, Mallouri D, Batsis I, Varelas C, Tagara S, Bousiou Z, Papathanasiou M, Vardi A, Papalexandri A, Vadikoliou C, Athanasiadou A, Lalayanni C, Fylaktou A, Antoniadis K, Anagnostopoulos A. Sakellari I, et al. Among authors: papathanasiou m. Transplant Cell Ther. 2021 Nov;27(11):916.e1-916.e6. doi: 10.1016/j.jtct.2021.07.020. Epub 2021 Jul 25. Transplant Cell Ther. 2021. PMID: 34320443 Free article.
Blast Crisis of CML After TKI Discontinuation in a Patient With Previous Stable Deep Molecular Response: Is It Safe to Stop?
Papalexandri A, Saloum R, Touloumenidou T, Papathanasiou M, Lalayanni C, Baldoumi E, Demosthenous C, Zerva P, Koutra MG, Athanasiadou A, Anagnostopoulos A. Papalexandri A, et al. Among authors: papathanasiou m. Hemasphere. 2018 Nov 12;2(6):e157. doi: 10.1097/HS9.0000000000000157. eCollection 2018 Dec. Hemasphere. 2018. PMID: 31723795 Free PMC article. No abstract available.
Allografted recipients immunized against hepatitis B virus are at high risk of gradual surface antibody (HbsAb) disappearance post transplant, regardless of adoptive immunity transfer.
Kaloyannidis P, Batsis I, Yannaki E, Adamidou D, Bartzoudis D, Papathanasiou M, Mallouri D, Sakellari I, Fassas A, Anagnostopoulos A. Kaloyannidis P, et al. Among authors: papathanasiou m. Biol Blood Marrow Transplant. 2007 Sep;13(9):1049-56. doi: 10.1016/j.bbmt.2007.05.009. Epub 2007 Jul 16. Biol Blood Marrow Transplant. 2007. PMID: 17697967 Free article.
Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience.
Katodritou E, Terpos E, Kastritis E, Delimpasis S, Symeonidis AS, Repousis P, Kyrtsonis MC, Vadikolia C, Michalis E, Polychronidou G, Michael M, Papadaki S, Papathanasiou M, Kokoviadou K, Kioumi A, Vlachaki E, Hadjiaggelidou C, Kouraklis A, Patsias I, Gavriatopoulou M, Kotsopoulou M, Verrou E, Gastari V, Christoulas D, Giannopoulou E, Pouli A, Konstantinidou P, Anagnostopoulos A, Dimopoulos MA. Katodritou E, et al. Among authors: papathanasiou m. Ann Hematol. 2015 Dec;94(12):2033-42. doi: 10.1007/s00277-015-2484-y. Epub 2015 Sep 30. Ann Hematol. 2015. PMID: 26420061 Clinical Trial.
Orbital involvement in Castleman disease.
Venizelos I, Papathomas TG, Papathanasiou M, Cheva A, Garypidou V, Coupland S. Venizelos I, et al. Among authors: papathanasiou m. Surv Ophthalmol. 2010 May-Jun;55(3):247-55. doi: 10.1016/j.survophthal.2009.09.003. Epub 2010 Jan 13. Surv Ophthalmol. 2010. PMID: 20070998 Review.
160 results